AI drug discovery company Iambic Therapeutics (formerly Entos) has raised USD 50 million in an extended Series B funding round led by new investors Mubadala Capital and Exor Ventures. Qatar Investment Authority and existing investors Abingworth and Illumina Ventures, among others, also participated.
The funding will be used to advance further Iambic's pipeline of clinical and preclinical oncology programs, including IAM1363, a brain-penetrant HER2 inhibitor in Phase I/I billion study, and a potential dual CDK2/4 inhibitor targeting treatment resistance in solid tumors.
In a previous Series B funding round in October 2023 , the company raised USD 100 million. The round was co-led by Ascenta Capital and Abingworth, with participation from several investors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.